Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
Open Access
- 19 December 2014
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 79 (1), 56-71
- https://doi.org/10.1111/bcp.12258
Abstract
In oncology trials, overall survival (OS) is considered the most reliable and preferred endpoint to evaluate the benefit of drug treatment. Other relevant variables are also collected from patients for a given drug and its indication, and it is important to characterize the dynamic effects and links between these variables in order to improve the speed and efficiency of clinical oncology drug development. However, the drug-induced effects and causal relationships are often difficult to interpret because of temporal differences. To address this, population pharmacokinetic-pharmacodynamic (PKPD) modelling and parametric time-to-event (TTE) models are becoming more frequently applied. Population PKPD and TTE models allow for exploration towards describing the data, understanding the disease and drug action over time, investigating relevance of biomarkers, quantifying patient variability and in designing successful trials. In addition, development of models characterizing both desired and adverse effects in a modelling framework support exploration of risk-benefit of different dosing schedules. In this review, we have summarized population PKPD modelling analyses describing tumour, tumour marker and biomarker responses, as well as adverse effects, from anticancer drug treatment data. Various model-based metrics used to drive PD response and predict OS for oncology drugs and their indications are also discussed.Keywords
Funding Information
- Swedish Cancer Society and DDMoRe (n°115156)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- EFPIA
- Academic and SME partners
- Genentech, Inc.
This publication has 63 references indexed in Scilit:
- PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib‐Treated Patients With GISTCPT: Pharmacometrics & Systems Pharmacology, 2013
- PKPD Modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTCPT: Pharmacometrics & Systems Pharmacology, 2013
- A Time to Event Tutorial for PharmacometriciansCPT: Pharmacometrics & Systems Pharmacology, 2013
- Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trialBMC Cancer, 2012
- Understanding the time course of pharmacological effect: a PKPD approachBritish Journal of Clinical Pharmacology, 2011
- Interpreting population pharmacokinetic‐pharmacodynamic analyses – a clinical viewpointBritish Journal of Clinical Pharmacology, 2011
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Journal of Pharmacokinetics and Pharmacodynamics, 2010
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Drug development in oncology: classical cytotoxics and molecularly targeted agentsBritish Journal of Clinical Pharmacology, 2006